BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29221819)

  • 1. Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.
    García-Cerro S; Vidal V; Lantigua S; Berciano MT; Lafarga M; Ramos-Cabrer P; Padro D; Rueda N; Martínez-Cué C
    Neurobiol Dis; 2018 Feb; 110():206-217. PubMed ID: 29221819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome.
    García-Cerro S; Martínez P; Vidal V; Corrales A; Flórez J; Vidal R; Rueda N; Arbonés ML; Martínez-Cué C
    PLoS One; 2014; 9(9):e106572. PubMed ID: 25188425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.
    Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal mineralization of the Ts65Dn Down syndrome mouse appendicular skeleton begins during embryonic development in a Dyrk1a-independent manner.
    Blazek JD; Malik AM; Tischbein M; Arbones ML; Moore CS; Roper RJ
    Mech Dev; 2015 May; 136():133-42. PubMed ID: 25556111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
    Altafaj X; Martín ED; Ortiz-Abalia J; Valderrama A; Lao-Peregrín C; Dierssen M; Fillat C
    Neurobiol Dis; 2013 Apr; 52():117-27. PubMed ID: 23220201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel inhibitor rescues cerebellar defects in a zebrafish model of Down syndrome-associated kinase Dyrk1A overexpression.
    Buchberger A; Schepergerdes L; Flaßhoff M; Kunick C; Köster RW
    J Biol Chem; 2021 Jul; 297(1):100853. PubMed ID: 34090874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice.
    Mazur-Kolecka B; Golabek A; Kida E; Rabe A; Hwang YW; Adayev T; Wegiel J; Flory M; Kaczmarski W; Marchi E; Frackowiak J
    J Neurosci Res; 2012 May; 90(5):999-1010. PubMed ID: 22252917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
    McElyea SD; Starbuck JM; Tumbleson-Brink DM; Harrington E; Blazek JD; Ghoneima A; Kula K; Roper RJ
    Hum Mol Genet; 2016 Nov; 25(22):4856-4869. PubMed ID: 28172997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
    Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
    Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a.
    Blazek JD; Abeysekera I; Li J; Roper RJ
    Hum Mol Genet; 2015 Oct; 24(20):5687-96. PubMed ID: 26206885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations.
    Toiber D; Azkona G; Ben-Ari S; Torán N; Soreq H; Dierssen M
    Neurobiol Dis; 2010 Oct; 40(1):348-59. PubMed ID: 20600907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of improved human cerebral organoids from single copy DYRK1A knockout induced pluripotent stem cells in trisomy 21: hypothetical solutions for neurodevelopmental models and therapeutic alternatives in down syndrome.
    Çağlayan ES
    Cell Biol Int; 2016 Dec; 40(12):1256-1270. PubMed ID: 27743462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome.
    Altafaj X; Ortiz-Abalia J; Fernández M; Potier MC; Laffaire J; Andreu N; Dierssen M; González-García C; Ceña V; Martí E; Fillat C
    Neurobiol Dis; 2008 Dec; 32(3):377-84. PubMed ID: 18773961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.
    Dowjat WK; Adayev T; Kuchna I; Nowicki K; Palminiello S; Hwang YW; Wegiel J
    Neurosci Lett; 2007 Feb; 413(1):77-81. PubMed ID: 17145134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triplication of DYRK1A causes retinal structural and functional alterations in Down syndrome.
    Laguna A; Barallobre MJ; Marchena MÁ; Mateus C; Ramírez E; Martínez-Cue C; Delabar JM; Castelo-Branco M; de la Villa P; Arbonés ML
    Hum Mol Genet; 2013 Jul; 22(14):2775-84. PubMed ID: 23512985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease.
    Ryoo SR; Cho HJ; Lee HW; Jeong HK; Radnaabazar C; Kim YS; Kim MJ; Son MY; Seo H; Chung SH; Song WJ
    J Neurochem; 2008 Mar; 104(5):1333-44. PubMed ID: 18005339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.
    Altafaj X; Dierssen M; Baamonde C; Martí E; Visa J; Guimerà J; Oset M; González JR; Flórez J; Fillat C; Estivill X
    Hum Mol Genet; 2001 Sep; 10(18):1915-23. PubMed ID: 11555628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
    Nguyen TL; Duchon A; Manousopoulou A; Loaëc N; Villiers B; Pani G; Karatas M; Mechling AE; Harsan LA; Limanton E; Bazureau JP; Carreaux F; Garbis SD; Meijer L; Herault Y
    Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30115750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a.
    Marechal D; Brault V; Leon A; Martin D; Lopes Pereira P; Loaëc N; Birling MC; Friocourt G; Blondel M; Herault Y
    Hum Mol Genet; 2019 May; 28(9):1561-1577. PubMed ID: 30649339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.